|
1
|
Mazziotti G, Canalis E and Giustina A:
Drug-induced osteoporosis: Mechanisms and clinical implications. Am
J Med. 123:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Panday K, Gona A and Humphrey MB:
Medication-induced osteoporosis: Screening and treatment
strategies. Ther Adv Musculoskelet Dis. 6:185–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bilen O and Teruya J: Complications of
anticoagulation. Dis Mon. 58:440–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rajgopal R, Bear M, Butcher MK and
Shaughnessy SG: The effects of heparin and low molecular weight
heparins on bone. Thromb Res. 122:293–298. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duggan ST, Scott LJ and Plosker GL:
Rivaroxaban: A review of its use for the prevention of venous
thromboembolism after total hip or knee replacement surgery. Drugs.
69:1829–1851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klüter T, Weuster M, Brüggemann S,
Menzdorf L, Fitschen-Oestern S, Steubesand N, Acil Y, Pufe T,
Varoga D, Seekamp A and Lippross S: Rivaroxaban does not impair
fracture healing in a rat femur fracture model: An experimental
study. BMC Musculoskelet Disord. 16:792015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Somjen D, Katzburg S, Gigi R, Dolkart O,
Sharon O, Salai M and Stern N: Rivaroxaban, a direct inhibitor of
the coagulation factor Xa interferes with hormonal-induced
physiological modulations in human female osteoblastic cell line
SaSO2. J Steroid Biochem Mol Biol. 135:67–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gigi R, Salai M, Dolkart O, Chechik O,
Katzburg S, Stern N and Somjen D: The effects of direct factor Xa
inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2.
Connect Tissue Res. 53:446–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xia J, Zhang Z, Wang J, Zu J, Wang N and
Wang D: Comparison of the effects of heparin and the direct factor
Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in
adult rats. Connect Tissue Res. 56:477–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saijo M, Kitazawa R, Nakajima M, Kurosaka
M, Maeda S and Kitazawa S: Heparanase mRNA expression during
fracture repair in mice. Histochem Cell Biol. 120:493–503. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kram V, Zcharia E, Yacoby-Zeevi O, Metzger
S, Chajek-Shaul T, Gabet Y, Müller R, Vlodavsky I and Bab I:
Heparanase is expressed in osteoblastic cells and stimulates bone
formation and bone mass. J Cell Physiol. 207:784–792. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smith PN, Freeman C, Yu D, Chen M, Gatenby
PA, Parish CR and Li RW: Heparanase in primary human osteoblasts. J
Orthop Res. 28:1315–1322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ornitz DM and Marie PJ: Fibroblast growth
factor signaling in skeletal development and disease. Genes Dev.
29:1463–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takei Y, Minamizaki T and Yoshiko Y:
Functional diversity of fibroblast growth factors in bone
formation. Int J Endocrinol. 2015:7293522015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hurley MM, Marie PJ and Florkiewics RZ:
Fibroblast Growth Factor and Fibroblast Growth Factor Receptor
Families. Principles of Bone Biology. Bilezikian JP, Raisz LG and
Rodan G: San Diego, CA: Academic Press; pp. 627–645. 2002
|
|
16
|
Debiais F, Hott M, Graulet AM and Marie
PJ: The effects of fibroblast growth factor-2 on human neonatal
calvaria osteoblastic cells are differentiation stage specific. J
Bone Miner Res. 13:645–654. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Solayar GN, Walsh PM and Mulhall KJ: The
effect of a new direct factor Xa inhibitor on human osteoblasts: An
in-vitro study comparing the effect of rivaroxaban with enoxaparin.
BMC Musculoskelet Disord. 12:2472011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ramani VC, Yang Y, Ren Y, Nan L and
Sanderson RD: Heparanase plays a dual role in driving hepatocyte
growth factor (HGF) signaling by enhancing HGF expression and
activity. J Biol Chem. 286:6490–6499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brown AJ, Alicknavitch M, D'Souza SS,
Daikoku T, Kirn-Safran CB, Marchetti D, Carson DD and Farach-Carson
MC: Heparanase expression and activity influences chondrogenic and
osteogenic processes during endochondral bone formation. Bone.
43:689–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han Q, Liu F and Zhou Y: Increased
expression of heparanase in osteogenic differentiation of rat
marrow stromal cells. Exp Ther Med. 5:1697–1700. 2013.PubMed/NCBI
|
|
22
|
Fei Y, Gronowicz G and Hurley MM:
Fibroblast growth factor-2, bone homeostasis and fracture repair.
Curr Pharm Des. 19:3354–3363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marie PJ, Miraoui H and Sévère N: FGF/FGFR
signaling in bone formation: Progress and perspectives. Growth
Factors. 30:117–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Montero A, Okada Y, Tomita M, Ito M,
Tsurukami H, Nakamura T, Doetschman T, Coffin JD and Hurley MM:
Disruption of the fibroblast growth factor-2 gene results in
decreased bone mass and bone formation. J Clin Invest.
105:1085–1093. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao L, Ueno D, Catros S, Homer-Bouthiette
C, Charles L, Kuhn L and Hurley MM: Fibroblast growth factor-2
isoform (low molecular weight/18 kDa) overexpression in
preosteoblast cells promotes bone regeneration in critical size
calvarial defects in male mice. Endocrinology. 155:965–974. 2014.
View Article : Google Scholar : PubMed/NCBI
|
